Drug Enforcement Administration September 2021 – Federal Register Recent Federal Regulation Documents

Bulk Manufacturer of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.
Document Number: 2021-21101
Type: Notice
Date: 2021-09-29
Agency: Drug Enforcement Administration, Department of Justice
Cambridge Isotope Laboratories, Inc., has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTAL INFORMATION listed below for further drug information.
Importer of Controlled Substances Application: Groff NA Hemplex, LLC
Document Number: 2021-20887
Type: Notice
Date: 2021-09-27
Agency: Drug Enforcement Administration, Department of Justice
Groff NA Hemplex, LLC. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
Bulk Manufacturer of Controlled Substances Application: PCI Synthesis
Document Number: 2021-20762
Type: Notice
Date: 2021-09-24
Agency: Drug Enforcement Administration, Department of Justice
PCI Synthesis has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
Importer of Controlled Substances Application: Cardinal Health
Document Number: 2021-20760
Type: Notice
Date: 2021-09-24
Agency: Drug Enforcement Administration, Department of Justice
Cardinal Health has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
Salman Akbar, M.D.; Decision and Order
Document Number: 2021-20247
Type: Notice
Date: 2021-09-20
Agency: Drug Enforcement Administration, Department of Justice
Humberto A. Florian, M.D.; Decision and Order
Document Number: 2021-20246
Type: Notice
Date: 2021-09-20
Agency: Drug Enforcement Administration, Department of Justice
Steven P. French, M.D.; Decision and Order
Document Number: 2021-20245
Type: Notice
Date: 2021-09-20
Agency: Drug Enforcement Administration, Department of Justice
Lisa M. Jones, N.P.; Dismissal of Proceedings
Document Number: 2021-20241
Type: Notice
Date: 2021-09-20
Agency: Drug Enforcement Administration, Department of Justice
Addition of the United States Space Force as a Registration Waiver and Registration Fee Exempt Military Entity
Document Number: 2021-19984
Type: Rule
Date: 2021-09-17
Agency: Drug Enforcement Administration, Department of Justice
This final rule amends existing regulations to include the United States Space Force as a registration waiver and registration fee exempt military entity.
Importer of Controlled Substances Application: Cambridge Isotope Laboratories
Document Number: 2021-19944
Type: Notice
Date: 2021-09-15
Agency: Drug Enforcement Administration, Department of Justice
Cambridge Isotope Laboratories has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
Bulk Manufacturer of Controlled Substances Application: Eli-Elsohly Laboratories
Document Number: 2021-19679
Type: Notice
Date: 2021-09-13
Agency: Drug Enforcement Administration, Department of Justice
Eli-Elsohly Laboratories has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Bulk Manufacturer of Controlled Substances Application: Cayman Chemical Company
Document Number: 2021-19632
Type: Notice
Date: 2021-09-13
Agency: Drug Enforcement Administration, Department of Justice
Cayman Chemical Company, has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Importer of Controlled Substances Application: Aurobindo Pharma USA, Inc.
Document Number: 2021-19631
Type: Notice
Date: 2021-09-13
Agency: Drug Enforcement Administration, Department of Justice
Aurobindo Pharma USA, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Bulk Manufacturer of Controlled Substances Application: Bulk Manufacturer of Marihuana: Amethyst Exploration, LLC
Document Number: 2021-19629
Type: Notice
Date: 2021-09-13
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) is providing notice of an application it has received from an entity applying to be registered to manufacture in bulk basic class(es) of controlled substances listed in schedule I. DEA intends to evaluate this and other pending applications according to its regulations governing the program of growing marihuana for scientific and medical research under DEA registration.
Lora L. Thaxton, M.D.; Decision and Order
Document Number: 2021-19203
Type: Notice
Date: 2021-09-07
Agency: Drug Enforcement Administration, Department of Justice
Uvienome Linda Sakor, N.P.; Decision and Order
Document Number: 2021-19194
Type: Notice
Date: 2021-09-07
Agency: Drug Enforcement Administration, Department of Justice
Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021
Document Number: 2021-18935
Type: Notice
Date: 2021-09-02
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration proposes to adjust the 2021 aggregate production quotas for several controlled substances in schedules I and II of the Controlled Substances Act and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.
Schedules of Controlled Substances: Placement of Methiopropamine in Schedule I
Document Number: 2021-18843
Type: Proposed Rule
Date: 2021-09-02
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration proposes placing N-methyl- 1-(thiophen-2-yl)propan-2-amine (methiopropamine), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle methiopropamine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.